BRPI0517286A - modulação de rnai de rsv, piv e outras viroses respiratórias e empregos desta - Google Patents

modulação de rnai de rsv, piv e outras viroses respiratórias e empregos desta

Info

Publication number
BRPI0517286A
BRPI0517286A BRPI0517286-1A BRPI0517286A BRPI0517286A BR PI0517286 A BRPI0517286 A BR PI0517286A BR PI0517286 A BRPI0517286 A BR PI0517286A BR PI0517286 A BRPI0517286 A BR PI0517286A
Authority
BR
Brazil
Prior art keywords
rsv
piv
rnai
modulation
jobs
Prior art date
Application number
BRPI0517286-1A
Other languages
English (en)
Inventor
Sailen Barik
Original Assignee
Univ South Alabama
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Alabama filed Critical Univ South Alabama
Publication of BRPI0517286A publication Critical patent/BRPI0517286A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

MODULAçãO DE RNAi DE RSV, PIV E OUTRAS VIROSES RESPIRATóRIAS E EMPREGOS DESTA. A presente invenção é baseada na demonstração in vivo de que RSV e PIV pode ser inibido através da administração intranasal de agentes de RNAi, bem como por administração parenteral de tais agentes. Além disso, é mostrado que a redução viral eficaz pode ser obtida com mais do que um vírus sendo tratado concomitantemente. Com base nestas descobertas, a presente invenção fornece composições e métodos específicos e gerais que são úteis na redução dos níveis de mRNA de RSV ou PIV, níveis de proteína de RSV ou PIVe os títulos virais em um indivíduo, por exemplo, um mamífero, tal como um humano. Estas descobertas podem ser aplicadas a outras viroses respiratórias.
BRPI0517286-1A 2004-10-22 2005-10-21 modulação de rnai de rsv, piv e outras viroses respiratórias e empregos desta BRPI0517286A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US62155204P 2004-10-22 2004-10-22
US11/151,976 US20060089324A1 (en) 2004-10-22 2005-06-14 RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
US11/151,893 US7592322B2 (en) 2004-10-22 2005-06-14 RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
PCT/US2005/038269 WO2006062596A2 (en) 2004-10-22 2005-10-21 RNAi MODULATION OF RSV, PIV AND OTHER RESPIRATORY VIRUSES AND USES THEREOF

Publications (1)

Publication Number Publication Date
BRPI0517286A true BRPI0517286A (pt) 2008-10-07

Family

ID=36578352

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517286-1A BRPI0517286A (pt) 2004-10-22 2005-10-21 modulação de rnai de rsv, piv e outras viroses respiratórias e empregos desta

Country Status (12)

Country Link
US (2) US7592322B2 (pt)
EP (1) EP1806968B1 (pt)
JP (1) JP5037349B2 (pt)
KR (1) KR101193825B1 (pt)
CN (1) CN101087527B (pt)
AU (1) AU2005314617B2 (pt)
BR (1) BRPI0517286A (pt)
CA (1) CA2584309A1 (pt)
MX (1) MX2007004692A (pt)
NO (1) NO20071953L (pt)
RU (1) RU2494745C2 (pt)
WO (1) WO2006062596A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003064626A2 (en) 2002-02-01 2003-08-07 Sequitur, Inc. Double-stranded oligonucleotides
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
WO2003064621A2 (en) 2002-02-01 2003-08-07 Ambion, Inc. HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
US8258288B2 (en) * 2002-02-20 2012-09-04 Sirna Therapeutics, Inc. RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
US7297786B2 (en) * 2004-07-09 2007-11-20 University Of Iowa Research Foundation RNA interference in respiratory epitheial cells
US7790878B2 (en) * 2004-10-22 2010-09-07 Alnylam Pharmaceuticals, Inc. RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
EA012573B1 (ru) * 2005-01-07 2009-10-30 Элнилэм Фармасьютикалз, Инк. РНКi МОДУЛЯЦИЯ RSV И ЕЁ ТЕРАПЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ
US20100129437A1 (en) 2007-03-23 2010-05-27 Bbb Holding B.V. Targeted intracellular delivery of antiviral agents
JP2010527914A (ja) * 2007-04-26 2010-08-19 クォーク ファーマシューティカルズ インコーポレーティッド 呼吸器系への抑制性核酸分子の治療的送達
WO2009055445A2 (en) * 2007-10-22 2009-04-30 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2229459B1 (en) * 2007-12-13 2014-08-27 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of RSV infection
WO2010011895A1 (en) * 2008-07-25 2010-01-28 Alnylam Pharmaceuticals, Inc. Enhancement of sirna silencing activity using universal bases or mismatches in the sense strand
US20100168205A1 (en) * 2008-10-23 2010-07-01 Alnylam Pharmaceuticals, Inc. Methods and Compositions for Prevention or Treatment of RSV Infection Using Modified Duplex RNA Molecules
EP2545172B2 (en) 2010-03-08 2017-12-06 Novartis AG Methods of testing for intracellular pathogens
SG10201604479YA (en) * 2011-03-03 2016-07-28 Quark Pharmaceuticals Inc Oligonucleotide Modulators Of The Toll-Like Receptor Pathway
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
SG193990A1 (en) * 2011-04-08 2013-11-29 Bio Rad Laboratories Pcr reaction mixtures with decreased non-specific activity
US11163898B2 (en) * 2013-09-11 2021-11-02 Mimecast Services Ltd. Sharing artifacts in permission-protected archives
EA201790534A1 (ru) 2014-09-07 2017-07-31 Селекта Байосайенсиз, Инк. Способы и композиции для ослабления иммунных ответов против вирусного вектора для переноса, предназначенного для генной терапии
EP3198017B1 (en) 2014-09-26 2021-01-06 The U.S.A. as represented by the Secretary, Department of Health and Human Services Virus-based expression vectors and uses thereof
MX2020003838A (es) 2017-10-13 2020-08-06 Selecta Biosciences Inc Metodos y composiciones para atenuar las respuestas de inmunoglobulina m del vector de transferencia antiviral.
CA3141863A1 (en) 2019-05-28 2020-12-03 Selecta Biosciences, Inc. Methods and compositions for attenuated anti-viral transfer vector immune response
KR20230022150A (ko) * 2020-03-13 2023-02-14 누오-베타 파마슈티컬 테크놀로지 (상하이) 씨오., 엘티디. Pi4k 억제제의 항-코로나바이러스 효과 및 적용
WO2021252557A1 (en) * 2020-06-09 2021-12-16 Alnylam Pharmaceuticals, Inc. Rnai compositions and methods of use thereof for delivery by inhalation
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
EP4527927A1 (en) * 2023-09-22 2025-03-26 Medizinische Hochschule Hannover Oligonucleotide-based strategies to combat respiratory viruses

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) * 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US5693532A (en) * 1994-11-04 1997-12-02 Ribozyme Pharmaceuticals, Inc. Respiratory syncytial virus ribozymes
WO1997014792A2 (en) * 1995-10-17 1997-04-24 Hybridon, Inc. Oligonucleotides with anti-respiratory syncytial virus activity
US6214805B1 (en) * 1996-02-15 2001-04-10 The United States Of America As Represented By The Department Of Health And Human Services RNase L activators and antisense oligonucleotides effective to treat RSV infections
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
DE60130583T3 (de) * 2000-12-01 2018-03-22 Europäisches Laboratorium für Molekularbiologie Kleine rns moleküle, die rns-interferenz vermitteln
EP1390472A4 (en) * 2001-05-29 2004-11-17 Sirna Therapeutics Inc NUCLEIC ACID TREATMENT OF DISEASES OR SIDES RELATED TO RAS, HER2 AND HIV LEVELS
AU2002313699A1 (en) * 2001-07-20 2003-03-03 Ribozyme Pharmacuticals, Inc. Enzymatic nucleic acid peptide conjugates
WO2003062258A1 (en) * 2002-01-22 2003-07-31 The Cleveland Clinic Foundation Rnase l activator-antisense complexes
US20030203868A1 (en) * 2002-02-06 2003-10-30 Bushman Frederic D. Inhibition of pathogen replication by RNA interference
AU2003299531A1 (en) * 2002-08-05 2004-06-07 University Of Massachusetts Compounds for modulating rna interference
WO2004029213A2 (en) * 2002-09-28 2004-04-08 Massachusetts Institute Of Technology Compositions and methods for delivery of short interfering rna and short hairpin rna
US20040242518A1 (en) * 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
AU2003291678B2 (en) * 2002-11-01 2009-01-15 The Trustees Of The University Of Pennsylvania Compositions and methods for siRNA inhibition of HIF-1 alpha
US20040220129A1 (en) * 2003-01-16 2004-11-04 The Trustees Of The University Of Pennsylvania Compositions and methods for siRNA inhibition of ICAM-1
WO2004064737A2 (en) 2003-01-17 2004-08-05 Alnylam Pharmaceuticals Therapeutics compositions
EP2216407B1 (en) 2003-03-07 2016-01-13 Alnylam Pharmaceuticals, Inc. Therapeutic compositions
CA2522349A1 (en) 2003-04-17 2004-11-04 Alnylam Pharmaceuticals, Inc. Protected monomers
EP2664672A1 (en) 2003-04-17 2013-11-20 Alnylam Pharmaceuticals Inc. Modified iRNA agents
WO2005056021A1 (en) * 2003-12-04 2005-06-23 University Of South Florida Polynucleotides for reducing respiratory syncytial virus gene expression
US7297786B2 (en) 2004-07-09 2007-11-20 University Of Iowa Research Foundation RNA interference in respiratory epitheial cells
EA012573B1 (ru) * 2005-01-07 2009-10-30 Элнилэм Фармасьютикалз, Инк. РНКi МОДУЛЯЦИЯ RSV И ЕЁ ТЕРАПЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ

Also Published As

Publication number Publication date
HK1114308A1 (en) 2008-10-31
AU2005314617A1 (en) 2006-06-15
EP1806968A4 (en) 2010-06-02
EP1806968A2 (en) 2007-07-18
CN101087527B (zh) 2012-01-18
CA2584309A1 (en) 2006-06-15
US20060089323A1 (en) 2006-04-27
RU2494745C2 (ru) 2013-10-10
RU2010139908A (ru) 2012-04-10
MX2007004692A (es) 2007-09-07
NO20071953L (no) 2007-05-18
KR101193825B1 (ko) 2012-10-23
CN101087527A (zh) 2007-12-12
JP2008517940A (ja) 2008-05-29
US20060089324A1 (en) 2006-04-27
JP5037349B2 (ja) 2012-09-26
KR20070106686A (ko) 2007-11-05
WO2006062596A3 (en) 2007-05-18
AU2005314617B2 (en) 2011-05-26
WO2006062596A2 (en) 2006-06-15
US7592322B2 (en) 2009-09-22
EP1806968B1 (en) 2012-12-05

Similar Documents

Publication Publication Date Title
BRPI0517286A (pt) modulação de rnai de rsv, piv e outras viroses respiratórias e empregos desta
WO2006074346A3 (en) RNAi MODULATION OF RSV AND THERAPEUTIC USES THEREOF
BRPI0516825A (pt) inibição da protease ns3-ns4a do vìrus da hepatite c (vhc)
BRPI0407587A (pt) inibidores do vìrus da hepatite c, composições e tratamentos que os utilizam
BRPI0514176A (pt) inibidores de replicação de hcv
BRPI0515646A (pt) proteìna de domìnio catalìtico de sialidase, molécula de ácido nucléico, proteìna de fusão, vetor de expressão, formulação farmacêutica, método de tratamento ou prevenção de infecção viral pelo vìrus de influenza, parainfluenza, ou syncytial respiratório, método de tratamento ou prevenção de infecção por um patógeno bacteriano, método de tratamento ou prevenção de alergia ou inflamação, método de intensificação da aplicação de gene por um vetor viral recombinante, método de tratamento ou prevenção de infecção por influenza
EP1575414A4 (en) METHODS AND DEVICES FOR DETECTION AND THERAPY OF ATHEROMOUS PLAQUES
GT201100056BA (es) Inhibidores macrocíclicos de serina proteasas de hepatitis c (segunda solicitud fraccionaria de la solicitud de patentes de invención no. a-2011-00056).
WO2003105770A3 (en) Carbocyclic nucleoside analogs as rna-antivirals
NO20085243L (no) Farmasoytisk sammensetning til behandling av virusinfeksjoner og/eller tumorsykdommer gjennom inhibering av proteinfolding og Proteinnedbryting
BR0112540A (pt) Peptìdios como inibidores da ns-3-serina protease do vìrus da hepatite c
EP1658304A4 (en) THERAPY ANTIGRIPPALE
BR0206614A (pt) Composto, composição farmacêutica, método para inibir a polimerase viral de rna dependente de rna e/ou inibir a replicação viral de rna dependente de rna, método para tratar uma infecção viral de rna dependente de rna, e, uso de um composto
EA200900298A1 (ru) Ингибиторы вируса гепатита с
BRPI0513866A (pt) composição, micropartìculas, método para o tratamento da hipertensão pulmonar, e dispositivo de inalação
EA201001276A1 (ru) Ингибиторы вируса гепатита с
DK1556021T3 (da) Farmaceutiske sammensætninger omfattende flavonoider og menthol samt fremgangsmåder til behandling med brug af nævnte sammensætninger
WO2009136979A3 (en) Compounds that modulate negative-sense, single-stranded rna virus replication and uses thereof
BR0211623A (pt) Agentes de contraste alvos multiméricos com base em peptìdeo
EA201590709A1 (ru) Комбинированная терапия и ее применение для лечения димиелинизирующих расстройств
BRPI0515316A (pt) compostos de imidazoquinolina
BR112013010525A2 (pt) tratamento de hbv
ATE522532T1 (de) Verbindungen zur behandlung von hepatitis c
BR112013020042A2 (pt) inibidores de vírus da hepatite c
ATE494291T1 (de) Verbindungen zur behandlung von hepatitis c

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2328 DE 18-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.